On Sep 8, Sanofi S.A. (NYSE: SNY) announced to acquire Kadmon Holdings, Inc. (NASDAQ: KDMN) in $1.9 billion deal, adding Rezurock™(belumosudil) to its transplant portfolio. Currently, BioNova is conducting a Phase 2 belumosudil (BN101) clinical trial for cGVHD in seven clinical centers in China and expecting to file NDA submission by the end of 2021.